BWXT vs EXPD
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
BWXT exhibits exceptional operational health with a Piotroski F-Score of 8/9 and strong growth metrics, but it is currently trading at a severe valuation premium. While earnings growth (31.1% YoY) and ROE (28.52%) are impressive, the current price of $223.15 far exceeds both the Graham Number ($32.91) and the growth-based Intrinsic Value ($105.31). The company is fundamentally a 'strong' business trapped in an 'expensive' stock, further complicated by bearish insider selling and a weak technical trend.
EXPD exhibits exceptional operational health with a Piotroski F-Score of 8/9 and a very conservative debt profile (Debt/Equity 0.24). However, the stock is severely overvalued, trading at $147.56—nearly 3x its Graham Number ($48.53) and 3.5x its Intrinsic Value ($41.65). This valuation gap is exacerbated by negative YoY revenue (-3.30%) and earnings growth (-11.50%), alongside a high PEG ratio of 3.80. With bearish insider selling and a 0/100 technical trend, the current price appears unsustainable relative to fundamental growth.
Compare Another Pair
Related Comparisons
BWXT vs EXPD: Head-to-Head Comparison
This page compares BWX Technologies, Inc. (BWXT) and Expeditors International of Washington, Inc. (EXPD) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.